Green tea epigallocatechin gallate exhibits anticancer effect in human pancreatic carcinoma cells via the inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor

Yuko Sato, Hoang Anh Vu, Yuuichi Beppu, Hoang Thanh Chi, Kousuke Sasaki, Hideaki Yamamoto, Phan Thi Xinh, Takashi Tanii, Yukihiko Hara, Toshiki Watanabe, Iwao Ohdomari

    研究成果: Article

    30 引用 (Scopus)

    抄録

    The exact molecular mechanism by which epigallocatechin gallate (EGCG) suppresses human pancreatic cancer cell proliferation is unclear. We show here that EGCG-treated pancreatic cancer cells AsPC-1 and BxPC-3 decrease cell adhesion ability on micro-pattern dots, accompanied by dephosphorylations of both focal adhesion kinase (FAK) and insulin-like growth factor-1 receptor (IGF-1R) whereas retained the activations of mitogen-activated protein kinase and mammalian target of rapamycin. The growth of AsPC-1 and BxPC-3 cells can be significantly suppressed by EGCG treatment alone in a dose-dependent manner. At a dose of 100M which completely abolishes activations of FAK and IGF-1R, EGCG suppresses more than 50 of cell proliferation without evidence of apoptosis analyzed by PARP cleavage. Finally, the MEK1/2 inhibitor U0126 enhances growth-suppressive effect of EGCG. Our data suggests that blocking FAK and IGF-1R by EGCG could prove valuable for targeted therapy, which can be used in combination with other therapies, for pancreatic cancer.

    元の言語English
    記事番号290516
    ジャーナルJournal of Biomedicine and Biotechnology
    2010
    DOI
    出版物ステータスPublished - 2010

    Fingerprint

    Focal Adhesion Protein-Tyrosine Kinases
    IGF Type 1 Receptor
    Tea
    Cells
    Somatomedin Receptors
    Somatomedins
    Pancreatic Neoplasms
    Cell proliferation
    Chemical activation
    Cell Proliferation
    Cell adhesion
    Sirolimus
    Growth
    Mitogen-Activated Protein Kinases
    Cell Adhesion
    Pancreatic Carcinoma
    epigallocatechin gallate
    Apoptosis
    Therapeutics

    ASJC Scopus subject areas

    • Biotechnology
    • Molecular Medicine
    • Genetics
    • Molecular Biology
    • Health, Toxicology and Mutagenesis
    • Medicine(all)

    これを引用

    Green tea epigallocatechin gallate exhibits anticancer effect in human pancreatic carcinoma cells via the inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor. / Sato, Yuko; Vu, Hoang Anh; Beppu, Yuuichi; Chi, Hoang Thanh; Sasaki, Kousuke; Yamamoto, Hideaki; Xinh, Phan Thi; Tanii, Takashi; Hara, Yukihiko; Watanabe, Toshiki; Ohdomari, Iwao.

    :: Journal of Biomedicine and Biotechnology, 巻 2010, 290516, 2010.

    研究成果: Article

    Sato, Yuko ; Vu, Hoang Anh ; Beppu, Yuuichi ; Chi, Hoang Thanh ; Sasaki, Kousuke ; Yamamoto, Hideaki ; Xinh, Phan Thi ; Tanii, Takashi ; Hara, Yukihiko ; Watanabe, Toshiki ; Ohdomari, Iwao. / Green tea epigallocatechin gallate exhibits anticancer effect in human pancreatic carcinoma cells via the inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor. :: Journal of Biomedicine and Biotechnology. 2010 ; 巻 2010.
    @article{fca88beaf8de4f85ae8f0965286a03e1,
    title = "Green tea epigallocatechin gallate exhibits anticancer effect in human pancreatic carcinoma cells via the inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor",
    abstract = "The exact molecular mechanism by which epigallocatechin gallate (EGCG) suppresses human pancreatic cancer cell proliferation is unclear. We show here that EGCG-treated pancreatic cancer cells AsPC-1 and BxPC-3 decrease cell adhesion ability on micro-pattern dots, accompanied by dephosphorylations of both focal adhesion kinase (FAK) and insulin-like growth factor-1 receptor (IGF-1R) whereas retained the activations of mitogen-activated protein kinase and mammalian target of rapamycin. The growth of AsPC-1 and BxPC-3 cells can be significantly suppressed by EGCG treatment alone in a dose-dependent manner. At a dose of 100M which completely abolishes activations of FAK and IGF-1R, EGCG suppresses more than 50 of cell proliferation without evidence of apoptosis analyzed by PARP cleavage. Finally, the MEK1/2 inhibitor U0126 enhances growth-suppressive effect of EGCG. Our data suggests that blocking FAK and IGF-1R by EGCG could prove valuable for targeted therapy, which can be used in combination with other therapies, for pancreatic cancer.",
    author = "Yuko Sato and Vu, {Hoang Anh} and Yuuichi Beppu and Chi, {Hoang Thanh} and Kousuke Sasaki and Hideaki Yamamoto and Xinh, {Phan Thi} and Takashi Tanii and Yukihiko Hara and Toshiki Watanabe and Iwao Ohdomari",
    year = "2010",
    doi = "10.1155/2010/290516",
    language = "English",
    volume = "2010",
    journal = "BioMed Research International",
    issn = "2314-6133",
    publisher = "Hindawi Publishing Corporation",

    }

    TY - JOUR

    T1 - Green tea epigallocatechin gallate exhibits anticancer effect in human pancreatic carcinoma cells via the inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor

    AU - Sato, Yuko

    AU - Vu, Hoang Anh

    AU - Beppu, Yuuichi

    AU - Chi, Hoang Thanh

    AU - Sasaki, Kousuke

    AU - Yamamoto, Hideaki

    AU - Xinh, Phan Thi

    AU - Tanii, Takashi

    AU - Hara, Yukihiko

    AU - Watanabe, Toshiki

    AU - Ohdomari, Iwao

    PY - 2010

    Y1 - 2010

    N2 - The exact molecular mechanism by which epigallocatechin gallate (EGCG) suppresses human pancreatic cancer cell proliferation is unclear. We show here that EGCG-treated pancreatic cancer cells AsPC-1 and BxPC-3 decrease cell adhesion ability on micro-pattern dots, accompanied by dephosphorylations of both focal adhesion kinase (FAK) and insulin-like growth factor-1 receptor (IGF-1R) whereas retained the activations of mitogen-activated protein kinase and mammalian target of rapamycin. The growth of AsPC-1 and BxPC-3 cells can be significantly suppressed by EGCG treatment alone in a dose-dependent manner. At a dose of 100M which completely abolishes activations of FAK and IGF-1R, EGCG suppresses more than 50 of cell proliferation without evidence of apoptosis analyzed by PARP cleavage. Finally, the MEK1/2 inhibitor U0126 enhances growth-suppressive effect of EGCG. Our data suggests that blocking FAK and IGF-1R by EGCG could prove valuable for targeted therapy, which can be used in combination with other therapies, for pancreatic cancer.

    AB - The exact molecular mechanism by which epigallocatechin gallate (EGCG) suppresses human pancreatic cancer cell proliferation is unclear. We show here that EGCG-treated pancreatic cancer cells AsPC-1 and BxPC-3 decrease cell adhesion ability on micro-pattern dots, accompanied by dephosphorylations of both focal adhesion kinase (FAK) and insulin-like growth factor-1 receptor (IGF-1R) whereas retained the activations of mitogen-activated protein kinase and mammalian target of rapamycin. The growth of AsPC-1 and BxPC-3 cells can be significantly suppressed by EGCG treatment alone in a dose-dependent manner. At a dose of 100M which completely abolishes activations of FAK and IGF-1R, EGCG suppresses more than 50 of cell proliferation without evidence of apoptosis analyzed by PARP cleavage. Finally, the MEK1/2 inhibitor U0126 enhances growth-suppressive effect of EGCG. Our data suggests that blocking FAK and IGF-1R by EGCG could prove valuable for targeted therapy, which can be used in combination with other therapies, for pancreatic cancer.

    UR - http://www.scopus.com/inward/record.url?scp=79953272160&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=79953272160&partnerID=8YFLogxK

    U2 - 10.1155/2010/290516

    DO - 10.1155/2010/290516

    M3 - Article

    C2 - 21318151

    AN - SCOPUS:79953272160

    VL - 2010

    JO - BioMed Research International

    JF - BioMed Research International

    SN - 2314-6133

    M1 - 290516

    ER -